Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01246908Phase 2Completed

Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression

Role: lead

NCT01633437Phase 1Completed

Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers

Role: lead

NCT00739908Phase 2Completed

A Study of CX157 (TriRima) for the Treatment of Depression

Role: lead

NCT01505907Phase 1Unknown

Pharmacokinetic Study of CXB909 in Healthy Male Subjects

Role: lead

NCT00814931Phase 1Completed

Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males

Role: lead

All 5 trials loaded